
Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer
For those with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), the first patients have been enrolled in the FORTIFI-HN01 study, which is a phase 2/3 trial of ficerafusp alfa (BCA101) in combination with Keytruda (pembrolizumab) …